AIRNA key facts
as of Oct 2026- Developer of a ribonucleic acid (RNA) editing platform designed for healthcare professionals.
- AIRNA is valued at approximately $339.0M as of Oct 2026 (last reported valuation).
- It has raised $245.0M; the latest was Early Stage VC ($155.0M) in Mar 2025.
- Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Venrock, Forbion, RTW Investments — 13 tracked in total.
- Status: Privately Held (backing).
AIRNA's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch AIRNA: the Monday email on marks, rounds and moves
AIRNA funding rounds
No funding rounds for AIRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs AIRNA
13+AIRNA valuation
AIRNA's last reported valuation was $339 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
AIRNA investors
13 investors are on record for AIRNA, including Alexandria Venture Investments, ARCH Venture Partners, Venrock and Forbion. By type, the record holds 3 venture capital firms, 1 hedge fund and 1 asset manager.
About AIRNA
Developer of a ribonucleic acid (RNA) editing platform designed for healthcare professionals. The company's platform is developing RNA editing therapeutics created to maximize therapeutic properties and address novel targets, enabling patients to get a cure for rare and common diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 50
- Website
- airna.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.